A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Inclusion Criteria: * Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the participant prior to performance of any study-specific procedure. * Female participants of non-childbearing potential may be enrolled in the clinical study. * Female participants of childbearing potential may be enrolled in the clinical study, if the participant: * has practiced adequate contraception for 1 month prior to study intervention administration, and * has a negative pregnancy test on the day of study intervention administration, and * has agreed to continue adequate contraception during the entire treatment period and for at least 1 month after completion of the study intervention administration series. * Blood sample for simultaneous follicle stimulating hormone (FSH) and estradiol levels may be collected. Additional inclusion criterion only for participants in Part 1 of the study (SLI): * Female and male between and including 18 through 64 YOA at the time of ICF signature. * Healthy participants, according to medical history, laboratory assessment and clinical examination at Screening Visit. Additional inclusion criterion only for participants in Part 2 of the study (PoP): * Females between and including 18 through 64 YOA at the time of ICF signature. * Female participants with documented history of at least 1 episode of urine culture confirmed E. coli uncomplicated UTI in …